Sign in
Taking peopleNo phase

Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Status
Recruiting
People taking part
1,800 people, planned
Started
10 Apr 2020
Planned end
Dec 2025
Type of study
Interventional, 12 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Administration procedures
Record updated
1 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patient ≥18 years old
  • Admitted to ICU with proven or suspected infection as the main diagnosis
  • Community acquired pneumonia related sepsis or vasopressors dependency (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine) or septic shock (vasopressor to maintain mean blood pressure of at least 65 mmHg and lactate levels above 2 mmol/l) or acute respiratory distress syndrome (ARDS: a- acute onset, i.e. within one week of an apparent clinical insult and with progression of respiratory syndrome, b- bilateral opacities on chest imaging not explained by other pulmonary pathologies, e.g. pleural effusion, atelectasis, nodules etc, c- no evidence for heart failure or volume overload, d- PaO2/FiO2 ≤ 300 mm Hg, - PEEP ≥ 5 cm H2O
  • Patients who have been tested for one or more RECORDS specific biomarkers:; CIRCI; Endocan; GILZ; DUSP-1; MDW; lymphopenia; Transcriptomic SRS2; Endotype B; PCR COVID-19; PCR Influenza; PCR other respiratory virus; Cutaneous vasoconstrictor response to glucocorticoids
  • Patient who has signed an informed and written consent whevener he/she is able of consent, if not, if not ascent from his/her representant whenever he/she is present at time of screening for inclusion
  • Patient affiliated to a social security system or to an universal health coverage (Couverture Maladie Universelle (CMU) in France
  • Patient under guardianship or curatorship will be included
  • Patient in case of simple emergency (legal definition) will be included
  • Patients managed with covid 19 and having biological samples available

Who cannot take part

  • Previously enrolled in this study
  • Formal indication for corticosteroids according to most recent international guidelines
  • Hypersensitivity to hydrocortisone or fludrocortisone or (microsined betamethasone dipropionate*) or any of their excipients (spc)
  • Nursing women * For patients included in this stratum, if applicable, do not apply the cream to an infected or ulcerated area
  • Pregnancy
  • Expected death or withdrawal of life-sustaining treatments within 48 hours
  • Vaccination with live virus within past 6 months
  • Women of childbearing potential not using contraception

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Main objective and primary endpoint: To compare the effect hydrocortisone plus fludrocortisone vs. placebo on a composite of death or persistent organ dysfunction - defined as continued dependency on mechanical ventilation, new renal replacement therapy, or vasopressors - assessed at 90 days on intensive care unit (ICU) adults and having different biological profiles for immune responses and corticosteroids bioactivity.

Read full original descriptionShow less

Secondary objectives and endpoints:

* Mortality and health-related quality of life at 6 months; * Daily organ function (SOFA score days 1, 2, 3, 4, 7, 10, 14, 28, and 90); * Daily secondary infections (up to 90 days) * Daily blood and urinary levels of glucose, sodium and potassium (up to 28 day) * Daily gastroduodenal bleeding (up to 28 day) * Daily cognitive function and muscles' strength (days 1 to 28, 90 and 180 days).

The 12 groups in the trial

  • Biomarker CIRCI neg: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker CIRCI neg: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

  • Biomarker endocan: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker endocan: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

  • Biomarker GILZ: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker GILZ: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

  • Biomarker CPD: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker CPD: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

  • Biomarker Transcriptomic SRS: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker Transcriptomic SRS: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

  • Biomarker Endotype B: Corticosteroid armTreatment being tested

    Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.

    Treatment: Administration procedures

  • Biomarker Endotype B: Placebo armPlacebo, for comparison

    Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.

    Treatment: Administration procedures

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicentre Concealed-Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for Corticotherapy
Publications
Record updated
1 October 2025